TY - JOUR TI - Rationale and design of the United Kingdom Heart Failure with Preserved Ejection Fraction Registry SN - 1355-6037 SP - 359 JF - Heart VL - 110 UR - https://eprints.gla.ac.uk/325399/ A1 - UK HFpEF Collaborative Group A1 - Y1 - 2024/02/12/ N2 - Objective Heart failure with preserved ejection fraction (HFpEF) is a common heterogeneous syndrome that remains imprecisely defined and consequently has limited treatment options and poor outcomes. Methods The UK Heart Failure with Preserved Ejection Fraction Registry (UK HFpEF) is a prospective data-enabled cohort and platform study. The study will develop a large, highly characterised cohort of patients with HFpEF. A biobank will be established. Deep clinical phenotyping, imaging, multiomics and centrally held national electronic health record data will be integrated at scale, in order to reclassify HFpEF into distinct subgroups, improve understanding of disease mechanisms and identify new biological pathways and molecular targets. Together, these will form the basis for developing diagnostics and targeted therapeutics specific to subgroups. It will be a platform for more effective and efficient trials, focusing on subgroups in whom targeted interventions are expected to be effective, with consent in place to facilitate rapid recruitment, and linkage for follow-up. Patients with a diagnosis of HFpEF made by a heart failure specialist, who have had natriuretic peptide levels measured and a left ventricular ejection fraction >40% are eligible. Patients with an ejection fraction between 40% and 49% will be limited to no more than 25% of the cohort. Conclusions UK HFpEF will develop a rich, multimodal data resource to enable the identification of disease endotypes and develop more effective diagnostic strategies, precise risk stratification and targeted therapeutics. N1 - Funding Study set-up and initial recruitment is funded by NIHR (reference NIHR301848). CAM, Advanced Fellowship, is funded by NIHR. CAM acknowledges support from the Manchester NIHR Biomedical Research Centre (NIHR203308) and the Manchester British Heart Foundation Accelerator Award (AA/18/4/34221). CS is Director of the British Heart Foundation Data Science Centre (at Health Data Research UK), which is funded by the British Heart Foundation. MCP and CB are supported by the British Heart Foundation Centre of Research Excellence Award (RE/13/5/30177 and RE/18/6/34217+). JM and MRW acknowledge support from the Imperial NIHR Biomedical Research Centre and the British Heart Foundation Imperial Centre of Research Excellence. JM is supported by a British Heart Foundation Consultant Research Award (FS/CRA/22/23036). SEP acknowledges support from the NIHR Barts Biomedical Research Centre. CM is directly and indirectly supported by the University College London Hospitals (UCLH) and Barts NIHR Biomedical Research Centres. SP acknowledges funding from the British Heart Foundation (CH/16/2/32089). MM is a British Heart Foundation Chair Holder (CH/16/3/32406) with British Heart Foundation Programme (RG/F/21/110053) Grant support. MFP holds a NIHR Clinical Lectureship and acknowledges support from a British Heart Foundation Innovation Fund award. GPM is funded by an NIHR Research Professorship (RP-2017-08-ST2-007) and receives support for work in HFpEF from the NIHR Leicester Biomedical Research Centre and NIHR Leicester Clinical Research Facility. RZ, Advanced Fellowship, is funded by NIHR. RTL acknowledges support from the University College London Hospitals NHS Trust NIHR Biomedical Research Centre and the British Heart Foundation UCL Research Accelerator. ID - enlighten325399 AV - public EP - 365 PB - BMJ Publishing Group IS - 5 ER -